TimesSquare Capital Management LLC Raises Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

TimesSquare Capital Management LLC boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 31.9% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 193,516 shares of the company’s stock after purchasing an additional 46,857 shares during the quarter. IDEXX Laboratories makes up 1.2% of TimesSquare Capital Management LLC’s portfolio, making the stock its 24th largest position. TimesSquare Capital Management LLC’s holdings in IDEXX Laboratories were worth $80,007,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Chicago Partners Investment Group LLC increased its stake in IDEXX Laboratories by 16.7% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company’s stock worth $340,000 after buying an additional 96 shares in the last quarter. National Pension Service grew its position in shares of IDEXX Laboratories by 7.3% during the third quarter. National Pension Service now owns 185,972 shares of the company’s stock valued at $93,957,000 after purchasing an additional 12,647 shares in the last quarter. Insight Wealth Strategies LLC grew its position in shares of IDEXX Laboratories by 230.5% during the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock valued at $4,174,000 after purchasing an additional 7,041 shares in the last quarter. Larson Financial Group LLC grew its position in shares of IDEXX Laboratories by 17,238.5% during the third quarter. Larson Financial Group LLC now owns 2,254 shares of the company’s stock valued at $1,139,000 after purchasing an additional 2,241 shares in the last quarter. Finally, Quest Partners LLC grew its position in shares of IDEXX Laboratories by 4,059.4% during the third quarter. Quest Partners LLC now owns 2,870 shares of the company’s stock valued at $1,450,000 after purchasing an additional 2,801 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 1.0 %

Shares of NASDAQ IDXX opened at $449.06 on Wednesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The company has a market cap of $36.77 billion, a P/E ratio of 42.09, a PEG ratio of 3.35 and a beta of 1.37. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The firm has a 50-day simple moving average of $430.82 and a two-hundred day simple moving average of $452.56.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now directly owns 905 shares of the company’s stock, valued at approximately $380,498.20. The trade was a 27.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 13,330 shares of company stock valued at $6,161,276 over the last 90 days. Insiders own 2.18% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on IDXX. Bank of America raised their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Piper Sandler lifted their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Morgan Stanley dropped their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, February 5th. Finally, Barclays lifted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.